文献速递细菌感染、耐药与抗菌药物医院感染防控

未识别供体血流感染与实体器官移植受者结局的前瞻性队列研究

Association between unrecognized donor bloodstream infection and outcomes in solid organ transplant recipients: a prospective observational cohort study.
PubMed 文献 · Clin Microbiol Infect · 2026-03-27

该前瞻性观察性队列研究纳入2016至2022年单中心968例实体器官移植受者,评估器官获取时未知的供体血流感染与受者1年生存的关联。14%受者供体存在未识别血流感染,整体1年生存无显著差异,但供体为多重耐药血流感染时受者1年生存率显著降低,并发生5例碳青霉烯耐药肠杆菌目供体来源感染。

要点

  • 供体未识别血流感染整体与受者1年生存无显著关联。
  • 供体多重耐药血流感染与受者1年生存率降低独立相关。
  • 碳青霉烯耐药肠杆菌目传播率25%,均及时治疗且无感染相关死亡。

核心结论

  • 供体未识别血流感染整体不显著影响受者1年生存,但多重耐药血流感染可能不良影响受者结局。

研究设计与样本

  • 前瞻性观察性队列研究,纳入2016至2022年单中心968例实体器官移植受者,比较供体未识别血流感染暴露与未暴露受者。

主要发现

  • 968例受者中136例(14%)供体存在未识别血流感染,150株血培养分离株中67%(100/150)敏感、33%(50/150)多重耐药。
  • 供体未识别血流感染与受者1年生存无显著关联(校正HR 1.32,95%CI 0.86-2.03,P=0.12)。
  • 供体多重耐药血流感染受者1年生存率低于血培养阴性供体受者(校正HR 2.29,95%CI 1.08-4.87,P=0.04)。
  • 发生5例碳青霉烯耐药肠杆菌目供体来源感染,均为肝移植受者,传播率25%(5/20),均及时治疗且无感染相关死亡。

临床怎么用

  • 应通过主动监测系统及时识别供体血流感染并管理受者以降低供体来源感染风险。
  • 对供体多重耐药血流感染受者需加强术后监测与抗感染管理。

局限性

  • 单中心前瞻性队列研究,结论外推需谨慎。
  • 需进一步研究新型抗菌药物能否降低多重耐药供体血流感染相关风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The study aimed to evaluate the association between unrecognized donor bloodstream infection (BSI), unknown at organ procurement, and recipient 1-year survival. Incidence of donor-derived infections (DDIs) was assessed as a secondary outcome. METHODS: Prospective study including all solid organ transplant recipients conducted at Mediterranean Institute for Transplantation and Advanced Specialized Therapy from 2016 to 2022. Recipients from donors with unrecognized BSI were compared with unexposed recipients. Data were prospectively collected within our active surveillance system, implemented to promptly recognize donor BSI and manage recipients to mitigate unexpected DDIs. The association between donor unrecognized BSI and recipient 1-year survival was evaluated using survival curves adjusted for confounders at multivariable analysis with Cox proportional-hazard models. RESULTS: A total of 968 solid organ transplant recipients were included (472 livers, 330 kidneys, 86 hearts, and 80 lungs); 136 (14%) recipients had a donor with unrecognized BSI. Among 150 blood culture isolates, 67% (100 of 150) were susceptible, whereas 33% (50 of 150) were multidrug-resistant (MDR). Ninety skin contaminants were excluded from analysis. Carbapenem-resistant Enterobacterales (CRE) were the most common MDR microorganisms (20 of 50, 40%). One-year survival probability was comparable between recipients from donors with and without unrecognized BSI (adjusted hazard ratio, 1.32; 95% CI, 0.86-2.03, p 0.12). However, after stratification by microorganism type, recipients from donors with unrecognized MDR BSI had lower 1-year survival probability compared with recipients from blood culture-negative donors (adjusted hazard ratio, 2.29; 95% CI, 1.08-4.87, p 0.04). Five DDIs caused by CRE occurred, all in liver recipients. CRE transmission rate was 25% (5 of 20). These cases were promptly treated with no deaths attributable to the infection. CONCLUSIONS: In our cohort, 14% of recipients received organs from donors with BSI but only five CRE DDIs were observed. Receiving organs from donors with unrecognized MDR BSI may adversely affect recipient outcomes; further studies are needed to determine whether newer antimicrobial agents can mitigate this risk.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Cona A, Curatolo C, Giordani P, et al. Association between unrecognized donor bloodstream infection and outcomes in solid organ transplant recipients: a prospective observational cohort study. Clin Microbiol Infect. 2026. PMID: 41903603. doi:10.1016/j.cmi.2026.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。